AMED earnings

BATON ROUGE, La., May 3, 2023 /PRNewswire/ -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2023. Three-Month Periods Ended March 31, 2023 and 2022 Net service revenue increased $11.1 million to $556.4 million compared to $545.3 million in 2022.Net income attributable to Amedisys, Inc. of $25.2 million compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted share of $0.77 compared to $0.97 in 2022.Adjusted Quarterly Results* Adjusted EBITDA of $57.8 million compared to $66.3 million

All-Stock Transaction Combines Highly Complementary Businesses Unlocking Significant Benefits for Patients, Providers, Payers, and Care Teams Increases Access to High Quality Care for Communities Across the U.S. through a Unique National Clinical Platform Comprehensive Capabilities Across Alternate Site Care Spectrum Position Combined Company to Move Deeper into Value-Based Care Highly Attractive Combined Financial Profile Which Generated $6.2 Billion in Revenues and $622 Million in Adjusted EBITDA on a Combined Basis for Full Year 2022 Creates Stockholder Value Including Through Anticipated Annual Run-Rate Revenue and Cost Synergies of Approximately $75 Million by Year Three Following Clo

BATON ROUGE, La., April 20, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care, will report results for the first quarter ended March 31, 2023, after the market closes on May 3, 2023. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 4, 2023. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (888) 437-3179 (toll-free) or (862) 298-0702 (toll). A replay of the call will be available through June 4, 2023, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID 13737736. To access a live webcast of th

BATON ROUGE, La., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period and year ended December 31, 2022. Three-Month Periods Ended December 31, 2022 and 2021 Net service revenue increased $2.7 million to $562.0 million compared to $559.3 million in 2021.Net income attributable to Amedisys, Inc. of $31.7 million compared to $34.0 million in 2021.Net income attributable to Amedisys, Inc. per diluted share of $0.97 compared to $1.04 in 2021. Adjusted Quarterly Results* Adjusted EBITDA of $59.9 million compared to $64.8 million in 2021.Adjusted net service revenue of $562.0 million compared to $559.3 million in 2021

BATON ROUGE, La., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and nine-month periods ended September 30, 2022. Three-Month Periods Ended September 30, 2022 and 2021 Net service revenue increased $4.5 million to $558.0 million compared to $553.5 million in 2021.Net income attributable to Amedisys, Inc. of $25.6 million compared to $45.0 million in 2021.Net income attributable to Amedisys, Inc. per diluted share of $0.79 compared to $1.37 in 2021. Adjusted Quarterly Results* Adjusted EBITDA of $61.5 million compared to $72.4 million in 2021.Adjusted net service revenue of $558.9 million compared to $553.5 million in 2

BATON ROUGE, La., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, will report results for the third quarter ended September 30, 2022, after the market closes on October 26, 2022. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on October 27, 2022. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (toll-free) or (412) 902-1028 (toll). A replay of the call will be available through November 27, 2022, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID

BATON ROUGE, La., July 27, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2022. Three-Month Periods Ended June 30, 2022 and 2021 Net service revenue decreased $6.3 million to $557.9 million compared to $564.2 million in 2021.Net income attributable to Amedisys, Inc. of $29.6 million compared to $80.1 million in 2021.Net income attributable to Amedisys, Inc. per diluted share of $0.91 compared to $2.43 in 2021. Adjusted Quarterly Results* Adjusted EBITDA of $74.4 million compared to $83.8 million in 2021.Adjusted net service revenue of $566.3 million compared to $557.6 million in 2021.Adjuste

BATON ROUGE, La., July 06, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, will report results for the second quarter ended June 30, 2022, after the market closes on July 27, 2022. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on July 28, 2022. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (toll-free) or (412) 902-1028 (toll). A replay of the call will be available through August 28, 2022, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID 13731294. A

BATON ROUGE, La., April 27, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2022. Three-Month Periods Ended March 31, 2022 and 2021 Net service revenue increased $8.2 million to $545.3 million compared to $537.1 million in 2021.Net income attributable to Amedisys, Inc. of $31.7 million compared to $49.9 million in 2021.Net income attributable to Amedisys, Inc. per diluted share of $0.97 compared to $1.50 in 2021. Adjusted Quarterly Results* Adjusted EBITDA of $66.3 million compared to $78.6 million in 2021.Adjusted net income attributable to Amedisys, Inc. of $40.1 million compared to $51.1 million

BATON ROUGE, La., April 13, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, will report results for the first quarter ended March 31, 2022, after the market closes on April 27, 2022. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on April 28, 2022. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (toll-free) or (412) 902-1028 (toll). A replay of the call will be available through May 28, 2022, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID 13729119. A

BATON ROUGE, La., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period and year ended December 31, 2021. Three-Month Periods Ended December 31, 2021 and 2020 Net service revenue increased $8.6 million to $559.3 million compared to $550.7 million in 2020.Net income attributable to Amedisys, Inc. of $34.0 million compared to $45.2 million in 2020.Net income attributable to Amedisys, Inc. per diluted share of $1.04 compared to $1.36 in 2020. Adjusted Quarterly Results* Adjusted EBITDA of $64.8 million compared to $78.1 million in 2020.Adjusted net service revenue of $559.3 million compared to $550.7 million in 202

BATON ROUGE, La., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice, personal care and higher acuity care services, will report results for the fourth quarter and year ended December 31, 2021, after the market closes on February 23, 2022. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on February 24, 2022. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (toll-free) or (412) 902-1028 (toll). A replay of the call will be available through March 24, 2022, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering

BATON ROUGE, La., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and nine-month periods ended September 30, 2021. Three-Month Periods Ended September 30, 2021 and 2020 Net service revenue increased $9.4 million to $553.5 million compared to $544.1 million in 2020.Net income attributable to Amedisys, Inc. of $45.0 million compared to $72.0 million (inclusive of a $24.0 million income tax benefit related to executive stock option exercise) in 2020.Net income attributable to Amedisys, Inc. per diluted share of $1.37 compared to $2.16 (inclusive of $0.72 income tax benefit related to executive stock option exercise) in 2020.

BATON ROUGE, La., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice, personal care and higher acuity care services, will report results for the third quarter ended September 30, 2021, after the market closes on November 2, 2021. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on November 3, 2021. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (toll-free) or (412) 902-1028 (toll). A replay of the call will be available through December 3, 2021, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering acce

BATON ROUGE, La., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2021. Three-Month Periods Ended June 30, 2021 and 2020 Net service revenue increased $79.2 million to $564.2 million compared to $485.0 million in 2020.Net income attributable to Amedisys, Inc. of $80.1 million compared to $34.7 million in 2020.Net income attributable to Amedisys, Inc. per diluted share of $2.43 compared to $1.04 in 2020. Adjusted Quarterly Results* Adjusted EBITDA of $83.8 million compared to $66.4 million in 2020.Adjusted net service revenue of $557.6 million compared to $485.0 million in 2020.Adjus